Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia.

Creator(s)

Jenna Rossoff
Christina Baggott
Snehit Prabhu
Holly Pacenta
Christine L. Phillips
Heather Stefanski
Julie-An Talano
Amy Moskop
Steven P. Margossian
Michael R. Verneris
Douglas Myers, Children's Mercy HospitalFollow
Nicole Karras
Patrick A. Brown
Muna Qayed
Michelle Hermiston
Prakash Satwani
Christa Krupski
Amy K. Keating
Rachel Wilcox, Children's Mercy HospitalFollow
Cara A. Rabik
Vanessa A. Fabrizio
Michael Kunicki
Vasant Chinnabhandar
A Yasemin Goksenin
Kevin J. Curran
Crystal L. Mackall
Theodore W. Laetsch
Liora M. Schultz

Document Type

Article

Publication Date

11-25-2021

Identifier

DOI: 10.1182/blood.2021012392

Journal Title

Blood

Volume

138

Issue

21

First Page

2138

Last Page

2142

Recommended Citation

Rossoff J, Baggott C, Prabhu S, et al. Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia. Blood. 2021;138(21):2138-2142. doi:10.1182/blood.2021012392